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Introduction
Leveraging the generalized fasting and caloric restriction responses to mitigate metabolic disease is under 
intense investigation as a novel therapeutic approach against obesity, diabetes mellitus, and nonalcoholic 
fatty liver disease (NAFLD) (1, 2). The hepatocyte is uniquely positioned at the nexus of  the portal circula-
tion — where dietary macronutrients are sensed and triaged to their metabolic fate — and the peripheral 
circulation, from which macronutrients are taken up and utilized or stored. Its unique anatomic positioning 
also defines the hepatocyte’s role in coordinating the transition from fed to fasting states. Specifically, the 
hepatocyte senses fat, protein, and carbohydrate content and rapidly alters its metabolism and its endocrine 
functions to coordinate peripheral responses. However, the therapeutic promise of  caloric restriction and 
generalized macronutrient fasting remains limited by its clinical impracticality and unsustainability. Our 
laboratory and others (1, 9, 11) have therefore examined specific pathways through which fasting and 
fasting-like mechanisms can be molecularly or pharmacologically leveraged to the benefit of  the host.
Upon physiological macronutrient withdrawal, the canonical hepatic response is to shift to mobilize 
glycogen and oxidize fat from stores to produce glucose and ketone body fuel for the brain and heart. This 
begins with activation of  proximal macronutrient sensing kinases, AMPK, and mTOR. These kinases act 
as primary regulators of  macroautophagy as well as transcriptional fasting programming by hepatic tran-
scription factors, including transcription factor EB (3); PPARγ coactivator-1α (PGC1α) (4); and transcrip-
tional modifiers such as the sirtuin family of  protein deacetylases (5). FGF21 is released from the liver of  
fasting rodents and humans to promote adipose “browning” (mitochondrial uncoupling to promote heat 
generation; ref. 6). The net effect of  this signaling initiation is a networked cascade through which the liver 
The hepatic glucose fasting response is gaining traction as a therapeutic pathway to enhance 
hepatic and whole-host metabolism. However, the mechanisms underlying these metabolic effects 
remain unclear. Here, we demonstrate the epidermal-type lipoxygenase, eLOX3 (encoded by its 
gene, Aloxe3), is a potentially novel effector of the therapeutic fasting response. We show that 
Aloxe3 is activated during fasting, glucose withdrawal, or trehalose/trehalose analogue treatment. 
Hepatocyte-specific Aloxe3 expression reduced weight gain and hepatic steatosis in diet-induced 
and genetically obese (db/db) mouse models. Aloxe3 expression, moreover, enhanced basal 
thermogenesis and abrogated insulin resistance in db/db diabetic mice. Targeted metabolomics 
demonstrated accumulation of the PPARγ ligand 12-KETE in hepatocytes overexpressing Aloxe3. 
Strikingly, PPARγ inhibition reversed hepatic Aloxe3–mediated insulin sensitization, suppression of 
hepatocellular ATP production and oxygen consumption, and gene induction of PPARγ coactivator-
1α (PGC1α) expression. Moreover, hepatocyte-specific PPARγ deletion reversed the therapeutic 
effect of hepatic Aloxe3 expression on diet-induced insulin intolerance. Aloxe3 is, therefore, 
a potentially novel effector of the hepatocellular fasting response that leverages both PPARγ-
mediated and pleiotropic effects to augment hepatic and whole-host metabolism, and it is, thus, a 
promising target to ameliorate metabolic disease.
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provides energy substrate to the periphery during fasting and promotes peripheral insulin sensitivity for 
efficient absorption of  the next meal.
We recently demonstrated that blocking hepatic glucose transporters genetically or pharmacologically 
closely recapitulates the therapeutic metabolic effects of  generalized macronutrient fasting (7–11). Pharma-
cologic glucose transport blockade using the disaccharide glucose transporter inhibitor trehalose blocked 
mTOR and activated AMPK-dependent autophagic flux (9, 12). Moreover, trehalose blocked diet- and 
genetically induced steatosis via ATG16L1- and AMPK-dependent mechanisms, and it enhanced periph-
eral thermogenesis via hepatocyte TFEB- and FGF21-dependent mechanisms (11). Consistent with data 
from pharmacological glucose transporter (GLUT) blockade, genetic deletion of  the hepatocyte GLUT8 
similarly increased basal and fasting heat generation (10), enhanced hepatocyte fat oxidation, and inhibited 
hepatic de novo lipogenesis and triacylglycerol generation in mice fed a high-fructose diet (7, 8). Notably, 
in those experiments, GLUT8 blockade was associated with enhanced insulin tolerance, enhanced hepatic 
PPARγ expression, and concomitant activation of  the PPARγ target UCP2 (8). Conversely, GLUT8 was 
upregulated in the livers of  genetically diabetic mice (13). Together, prior data suggest that pharmacologic 
and genetic activation of  hepatic glucose fasting–like responses are sufficient to mitigate metabolic disease. 
However, the mechanisms underlying this protection remain enigmatic.
Recent data illuminate a role for cellular lipoxygenases in the pathogenesis and protection from meta-
bolic disease. In humans, a recent large cohort of  adults with type 2 diabetes demonstrated a potentially 
protective role for 5-lipoxygenases ALOX5 and ALOX5AP against diabetes mellitus (14). Conversely, 
ALOX12/15 inhibition in rodent models inhibited oxidative stress, β cell deterioration, hepatic steato-
sis, and systemic inflammation (15–18). Together, these data suggest that intracellular lipid intermediary 
metabolism drives both tissue-level and whole-organism metabolic homeostasis. The concept that the fast-
ing state might modulate lipoxygenase activity as part of  the broadly adaptive effects of  fasting on metabo-
lism remained heretofore unexplored.
Here, we identified eLOXE3 (encoded by the Aloxe3 gene) as a fasting-induced epidermal-type lipoxy-
genase that acts as a potentially novel effector of  the hepatic glucose fasting response in vitro and in vivo. 
Targeted Aloxe3 overexpression induced robust generation of  the PPARγ ligand (19, 20) 12-KETE. In vivo, 
hepatic Aloxe3 expression enhanced insulin sensitivity, attenuated weight gain, and reduced hepatic steato-
sis in both diet- and genetically induced steatosis models. Moreover, hepatic Aloxe3 expression mitigated 
diet-induced dyslipidemia, and db/db mice expressing Aloxe3 exhibited attenuated weight gain, enhanced 
basal caloric expenditure, and PPARγ-dependent insulin sensitivity. Strikingly, we demonstrate that hepa-
tocyte-specific PPARγ deletion is absolutely required for the insulin-sensitizing effect of  hepatic Aloxe3 
induction. Taken together, Aloxe3 is a fasting-responsive hepatocyte effector that is sufficient to attenuate 
insulin resistance, weight gain, and hepatic fat deposition in dietary and genetically obese models, in part 
by activating hepatic PPARγ. Aloxe3 is, thus, a novel therapeutic mechanism downstream of  the fasting 
response, which can be leveraged against metabolic disease.
Results
To test the hypothesis that Aloxe3 is induced by acute fasting or pseudo-fasting conditions, we sub-
jected WT mice to 48-hour fasting. During acute fasting, hepatic Aloxe3 expression was increased and 
sustained at least through 48 hours (Figure 1A). Oral administration of  the fasting-mimetic hepatic 
glucose transport inhibitor trehalose (3% PO, ad libitum), similarly induced Aloxe3 expression after 
24-hour and 48-hour trehalose feeding (Figure 1B). The hepatic Aloxe3 response to fasting contrasted 
with fasting Aloxe3 expression in white adipose tissue (WAT), wherein Aloxe3 mediates fat differentia-
tion and lipid storage. Accordingly, Aloxe3 was significantly suppressed during both fasting and treha-
lose feeding in epididymal WAT (Figure 1, A and B, respectively). We then modeled Aloxe3 expression 
in vitro to determine whether fasting-induced Aloxe3 expression is cell-autonomously regulated. Iso-
lated primary murine hepatocytes were subjected to treatment by either low serum and glucose (0.5% 
serum, 1 g/l glucose) or trehalose (Figure 1C). In addition, we characterized fasting-mimetic effects 
of  a trehalose analogue that resists enzymatic degradation by trehalases (21–23), called lactotreha-
lose (α-D-glucopyronosyl-(1,1)-α-D-galactopyranoside; Figure 1C and Supplemental Figure 1; supple-
mental material available online with this article; https://doi.org/10.1172/jci.insight.120794DS1). In 
each case, Aloxe3 expression was significantly increased, most potently by trehalose and lactotrehalose 
(Figure 1C and Supplemental Figure 1).
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In light of  evidence that Aloxe3 is a potentially novel hepatocyte fasting-responsive factor in mice 
and in isolated murine hepatocytes, we evaluated whether this factor is expressed in isolated human 
hepatocytes and in Huh7 and HepG2 human hepatoma cell lines. Consistent with immunoblot and 
immunohistochemical eLOX3 protein detection in human liver tissue (24), quantitative PCR (qPCR) 
analysis demonstrated ALOXE3 expression in both HepG2 and in primary human hepatocytes (Sup-
plemental Figure 2).
Figure 1. Aloxe3 is induced in response to fasting and pseudofasting. (A) Aloxe3 expression in liver and white adipose tissue (WAT) from fasting WT mice 
(0–48 hours [h]). n = 6 each of fed, 12 h fasting, and 24 h fasting mice. For 48 h fasting mice, n = 7. (B) Aloxe3 expression in WT mice fed oral trehalose (3% 
in sterile water fed ad libitum, 0–48 h). For control and trehalose (24 h) mice, n = 5 and 6. For 48 h trehalose-treated mice, n = 6. (C) Aloxe3 expression in 
isolated primary murine hepatocytes treated with 0.5% FCS/1 g/l glucose media, 100 mM trehalose, or 100 mM lactotrehalose (24 h). n = 4 per group. (D) 
Aloxe3 expression in trehalose-treated isolated primary hepatocytes pretreated with or without 5 mM pyruvate. n = 4 per group. (E) Aloxe3 expression in 
trehalose-treated WT and Atg16l1-mutant mice in vivo (24 h). n = 6 per group. (F) Aloxe3 expression in response to trehalose in the presence or absence of 
kinase-dead AMPK overexpression or siRNA-mediated AMPK knockdown. n = 4 per group. (G) Aloxe3 expression in response to trehalose in the presence or 
absence of antisense oligonucleotide (ASO) directed against PGC1, or FGF21. FGF receptor 1–4 inhibitor (LY2874455) was included as a control to demonstrate 
Aloxe3 blockade in context. n = 4 per group. (H) Fasting-responsive marker gene expression in the presence or absence of trehalose following treatment with 
or without Aloxe3-directed siRNA. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by 2-tailed t test with Bonferroni-Dunn post hoc correction versus 
untreated controls group or versus the bracketed comparison group where indicated.
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To determine whether Aloxe3 induction depended upon energy substrate deficit, we treated primary hepa-
tocytes with trehalose in the presence or absence of pyruvate. This provided energy substrate for the cell, inde-
pendently of glucose transporter blockade. Pyruvate reversed trehalose-induced Aloxe3 induction by ~60% (P 
< 0.0001), suggesting that Aloxe3 expression is at least partly energy substrate dependent (Figure 1D). In light 
of our prior data in which we demonstrated that the autophagy complex protein ATG16L1 was required for 
autophagic and antisteatotic effects of trehalose in hepatocytes (9, 25), we examined whether ATG16L1 is 
required for Aloxe3 induction. We treated primary hepatocytes from WT littermates or from mice with homo-
zygous hypomorphic Atg16l1 alleles (Atg16l1HM) with or without trehalose (24 hours). Aloxe3 mRNA quanti-
fication revealed robust Aloxe3 induction in WT hepatocytes, which was not suppressed in Atg16l1HM hepato-
cytes (Figure 1E). Similarly, AMPK inhibition (by kinase-dead AMPK overexpression or by Aloxe3 siRNA 
transfection; Figure 1F) and PPARα, PGC1α, and FGF21 knockdown each failed to reverse Aloxe3 induction 
Figure 2. Aloxe3 and trehalose induce the PPARγ ligand 12-KETE in murine hepatocytes. (A) Arachidonic acid metabolism mediated by lipoxygenases 
12-LOX, 5-LOX, and eLOX3 (adapted from refs. 26, 29, 58, 59). (B) Lipoxygenase activity in primary murine hepatocytes upon overexpression of β galacto-
sidase or Aloxe3. n = 3 from 1 representative experiment of 2 experiments with similar results. (C and D) Quantitative GC-MS analysis of the stable lipoxy-
genase reaction products 12-KETE, 5-HETE, and 12-HETE. Data represent 4 independent cultures per group from 1 experiment, representing 2 independent 
experiments with similar results. **P < 0.01 and ***P < 0.001 by 2-tailed t test with Bonferroni-Dunn post hoc correction versus untreated controls group 
or versus the bracketed comparison group where indicated.
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after trehalose treatment or glucose and serum withdrawal (Figures 1G and 1H). Accordingly, moderate hepa-
tocyte-specific overexpression of the fasting-induced transcription factor SIRT1 did not induce Aloxe3 expres-
sion (Supplemental Figure 3). In contrast, siRNA-based Aloxe3 knockdown attenuated PPARα and PGC1α at 
baseline and during glucose and serum withdrawal from hepatocytes in vitro, without effects on FGF21 expres-
sion (Figure 1H). Together, our data demonstrate that Aloxe3 is a hepatocyte lipoxygenase that is induced by 
glucose transporter blockade and energetic deficit via a mechanism that does not require canonical ATG16L1-
dependent and AMPK-PGC1α/PPARα-FGF21 fasting mechanisms.
eLOX3 generates the PPARγ ligand 12-KETE and an epoxyalcohol from 12-HpETE in the metabolism 
of  plasma membrane arachidonic acid (Figure 2A) (26–30). We tested whether Aloxe3 mediates similar lipid 
metabolism in hepatocytes upon forced Aloxe3 expression. We first evaluated the effect of  Aloxe3 overexpres-
sion on hepatocyte lipoxygenase activity by measuring LOX substrate oxidation in cell extracts from hepa-
tocytes overexpressing β galactosidase (β-gal) or Aloxe3. Consistent with prior data demonstrating intrinsic, 
latent dioxygenase activity of  eLOX3 (31), Aloxe3 overexpression significantly increased total oxidized LOX 
substrate accumulation (Figure 2B) and 12-KETE accumulation in primary hepatocytes (Figure 2C). This 
effect of  Aloxe3 overexpression on 12-KETE accumulation was indeed phenocopied by trehalose treatment 
(Figure 2C). Moreover, Aloxe3 overexpression decreased the abundance of  alternate arachidonic acid meta-
bolic pathway products 5-HETE and 12-HETE (Figure 2D).
To ascertain transcriptome-wide effects of  forced Aloxe3 overexpression, we next treated primary hepa-
tocytes with adenovirus encoding β-gal or Aloxe3 prior to RNA sequencing (RNA-seq) analysis. Pathway 
analysis revealed that 5 of  the 10 most downregulated processes in Aloxe3-overexpressing cells were devoted 
to inflammatory signaling, including TNFα, NF-κB, chemokine signaling, cytokine receptor signaling, and 
MAPK signaling (Figure 3A). Given these findings, and in light of  the fact that Aloxe3 upregulation by 
trehalose correlates with reduced diet- and genetically induced steatosis (9, 25), we examined whether 
Aloxe3 attenuates fat-induced inflammatory signaling and triglyceride (TG) accumulation. Primary hepa-
tocytes treated with BSA-conjugated fatty acids (FA) induced Il1b and Tnfa gene expression, as well as TG 
accumulation (Figure 3, B and C). These FA-induced effects on TG accumulation and Il1b and Tnfa gene 
expression effects were reversed in FA-treated cultures overexpressing Aloxe3.
Aloxe3-deficient mice are not amenable to in vivo metabolic studies because germline Aloxe3 deficiency 
results in postnatal mortality secondary to massive skin permeability and water loss (32). To evaluate the 
in vivo metabolic consequences of  hepatocyte Aloxe3 activation, we tested the in vivo effects of  hepatocyte-
directed Aloxe3 expression. We first confirmed overexpression of  the Aloxe3 transgene in liver (Figure 4A) 
without changes in Aloxe3 expression in skeletal muscle, WAT, or brown adipose tissue (not shown). This 
correlated with upregulation of  fasting and oxidative genes in unperturbed Aloxe3-overexpressing mice, 
including Aloxe3 (Figure 4A), Ppargc1a (PGC1), hepatocyte nuclear factor 4α (Hnf4A/HNF4α), and phos-
phoenolpyruvate carboxykinase 1 (Pck1, Figure 4A.).
We next evaluated the effect of  hepatic Aloxe3 expression in mice fed low-fat diet (LFD) or steatogenic, 
high trans-fat/cholesterol diet (HTFC) (12 weeks). Mice overexpressing Aloxe3 fed HTFC gained signifi-
cantly less weight, had lower total body mass (Figure 4B), and had lower body fat mass (Figure 4C) without 
changes in lean mass (not shown) when compared with Gfp-overexpressing mice fed HTFC. Accordingly, 
low density lipoprotein-cholesterol (LDL-C) and total cholesterol were significantly lowered in HTFC-fed 
mice overexpressing Aloxe3 (Figure 4D). Indices of  glucose homeostasis were also improved by Aloxe3 
overexpression in HTFC-fed mice (Figure 4, E–G). Specifically, HTFC feeding increased circulating insulin 
and homeostatic model assessment– insulin resistance (HOMA-IR) in GFP-overexpressing mice (Figure 
4, E and G), without altering fasting plasma glucose (Figure 4F). In contrast, HTFC-fed mice overexpress-
ing hepatic Aloxe3 were protected from HTFC-induced hyperinsulinemia and insulin resistance (Figure 
4, E and G). Indeed, fasting glucose was also lowered in Aloxe3-overexpressing, HTFC-fed mice when 
compared with GFP-expressing, HTFC-fed mice (Figure 4F). Together, hepatocyte Aloxe3 expression was 
sufficient to reduce diet-induced weight gain, body fat accumulation, dyslipidemia, and insulin resistance.
We next examined hepatic lipid metabolism in GFP- and Aloxe3-overexpressing mice fed LFD or HTFC. 
Frozen liver sections from HTFC-fed mice exhibited increased Oil Red O staining and macrosteatosis when 
compared with LFD-fed mice. Consistent with prior models of  PPARγ activation (33–35), Aloxe3 expression 
in LFD-fed mice resulted in a mild basal TG accumulation (Figure 5, A and B). However, we did not observe 
evidence of  hepatic inflammation or fibrosis by histological analysis of  H&E- or trichrome-stained liver 
sections in LFD-fed mice after 12 weeks Aloxe3 overexpression (Supplemental Figure 4). Also consistent 
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with prior reports on hepatic PPARγ activation, Aloxe3 overexpression modestly but significantly protected 
from HTFC-induced TG accumulation that took on a microsteatotic staining pattern (Figure 5, A and B). 
No changes in hepatic LDL-C or total cholesterol were observed (Figure 5, C and D) upon hepatic Aloxe3 
overexpression in LFD- or HTFC-fed mice. None of  our genetic or dietary manipulations had any effect on 
hepatic synthetic function, as ascertained by quantitative circulating albumin levels (Figure 5E).
To examine mechanistically how Aloxe3 might activate hepatocyte-starvation–like responses, we evalu-
ated the effects of  Aloxe3 overexpression on mitochondrial respiratory function at the cellular and molecular 
levels. RNA-seq analysis of  primary hepatocytes overexpressing Aloxe3 revealed that 6 of  the 10 most down-
regulated molecular processes encompassed mitochondrial electron transport function, including proton 
transport, ATPase activity, transmembrane ion transport, and hydrogen export (Figure 6A). We therefore 
tested functionally the hypothesis that Aloxe3 mitigates ATP production by inducing hepatocyte mitochon-
drial uncoupling. Seahorse analysis of  hepatocytes overexpressing Aloxe3 exhibited elevated proton leak, 
ATP production, and coupling efficiency, concomitant with suppressed basal oxygen consumption rate 
and enhanced glycolytic rate when compared with hepatocytes expressing β-gal (Figure 6B). Each of  these 
parameters was partly or fully reversed in the presence of  the PPARγ inhibitor GW9662 (Figure 6B). No 
changes in nonmitochondrial oxygen consumption were observed (Figure 6C), suggesting that Aloxe3 specifi-
cally affected mitochondrial energy metabolism.
Mechanistic interrogation in vivo was executed to determine whether hepatocyte Aloxe3 mediated periph-
eral insulin and glucose homeostasis in a leptin-dependent manner. To that end, we overexpressed Aloxe3 
or GFP in db/db mice, which lack the leptin receptor. Again, in the liver, we observed modest, statistically 
Figure 3. Aloxe3 reduces inflammatory signaling and steatosis in hepatocytes. (A) RNA-seq analysis of the top 9 downregulated genes in primary hepa-
tocytes expressing either β galactosidase or Aloxe3. n = 3 from a single RNA-seq run performed once. The P value for significantly downregulated pathways 
is demonstrated as (–Log[P value]). (B) Hepatic TG accumulation and (C) IL-1β or TNFα expression in hepatocytes treated with BSA-conjugated fatty acids 
with or without Aloxe3 expression. n = 4 in B and n = 4 in C, single representative experiments, which were repeated twice with similar results. ***P < 
0.001 and ****P < 0.0001 by 2-tailed t testing with Bonferroni-Dunn post hoc correction versus the bracketed comparison group as indicated.
7insight.jci.org   https://doi.org/10.1172/jci.insight.120794
R E S E A R C H  A R T I C L E
Figure 4. Enhanced whole-body metabolism in mice ALOXE3-overexpressing mice. (A) qPCR quantification of expression for oxidative and fasting-
response genes in unperturbed mice expressing hepatocyte GFP or Aloxe3. (B) Body weight over time in low-fat or high–trans fat/cholesterol diet–
fed mice expressing hepatocyte GFP or Aloxe3. (C) Body fat content in mice fed HTFC or LFD with or without hepatic Aloxe3 overexpression. (D)  
LDL-C and total cholesterol in mice fed HTFC or LFD with or without hepatic Aloxe3 overexpression. (E–G) Circulating insulin, glucose, and calcu-
lated HOMA-IR in LFD- and HTFC-fed mice overexpressing hepatocyte GFP or Aloxe3. Number of mice in each group is: 5, AAV8GFP LFD; 10, AAV8GFP 
HTFC; 5, AAV8ALOXE3 LFD; and 10, AAV8ALOXE3 HTFC. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by 2-tailed t test with Bonferroni-Dunn 
post hoc correction versus the bracketed comparison group as indicated.
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significant attenuation of  hepatic TG accumulation in db/db mice overexpressing Aloxe3 when compared 
with db/db controls (Figure 7, A and B). We confirmed Aloxe3 overexpression correlated with increases in 
oxidative and fasting-response genes Ppargc1a, Hnf4a, and Pc1 (Figure 7C). Moreover, Aloxe3 overexpression 
reduced genetic markers of  de novo lipogenesis in db/db mice, including Fsp27, Scd1, and Fasn (Figure 7D). 
Concomitant PPARγ inhibition by the inhibitor GW9662 produced either statistically significant or trends 
toward significant reversal in each of  these Aloxe3-altered marker genes (Figure 7, C and D).
Although baseline weights were not statistically different, db/db mice overexpressing Aloxe3 gained 
significantly less weight and had a lower end-of-trial weight than db/db mice over the 28-day trial (Figure 
8A). Indirect calorimetry revealed that the attenuated weight gain in aloxe3 db/db mice was associated 
with enhanced light- and dark-cycle heat generation and O2-CO2 exchange (Figure 8, B-D). Neither heat 
generation nor O2-CO2 exchange in Aloxe3
db/db was affected by GW9662 coadministration (Figure 8, B–D).
Because hepatic Aloxe3 expression enhanced peripheral insulin sensitivity in HTFC-fed mice 
(Figure4), and because PPARγ agonism by thiazolidinediones (TZDs) enhances peripheral insulin 
sensitivity (36, 37), we evaluated whether Aloxe3 enhances peripheral insulin and glucose homeosta-
sis dependent on PPARγ and yet independent of  the leptin receptor. Fasting circulating insulin and 
HOMA-IR were significantly lower in Aloxe3db/db mice without changes in circulating glucose when 
compared with db/db mice expressing GFP. The reduction in circulating insulin and HOMA-IR were 
reversed in mice concomitantly treated with the PPARγ inhibitor GW9662, suggesting that Aloxe3 
improves glucose and insulin homeostasis via a PPARγ-dependent mechanism. In contrast with our 
diet-induced model, however, targeted hepatic Aloxe3 expression did not reduce circulating lipids in 
a leptin receptor–deficient mice. Together, the data in our leptin-deficient model elucidate leptin- and 
PPARγ-dependent functions by Aloxe3.
Figure 5. Reduced hepatic steatosis correlates with Aloxe3-induced fasting responses. (A) Oil Red O staining in livers from low-fat or high–trans fat/
cholesterol–fed mice overexpressing GFP or Aloxe3. (B–D) Hepatic tissue quantification of triglycerides, LDL-C, total cholesterol in low-fat or high–trans 
fat/cholesterol–fed mice overexpressing empty vector or Aloxe3. (E) Serum albumin measurements in mice analyzed in A–D Number of mice in each group 
is: 5, AAV8GFP LFD; 10, AAV8GFP HTFC; 5, AAV8ALOXE3 LFD; and 10, AAV8ALOXE3 HTFC. Scale bar: 100 μm. **P < 0.01 and ****P < 0.0001 by 2-tailed t test with 
Bonferroni-Dunn post hoc correction versus untreated controls group or versus the bracketed comparison group where indicated.
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To gain further specificity regarding the role of hepatocyte PPARγ in Aloxe3-enhanced insulin sensitivity, we 
generated mice harboring a hepatocyte-specific PPARG deletion (hereafter referred to as PPARγ-LKO mice) by 
crossing mice with homozygous floxed Pparg alleles with mice expressing Cre recombinase driven by the albu-
min promoter. Mice were placed on a chow or Western diet (WD) to induce insulin resistance over 12 weeks; 
they were then subjected to insulin tolerance testing (ITT, Figure 9, A and B). Area under the ITT curve analysis 
revealed that WD feeding increased AUC in GFP-overexpressing animals, whereas AUC was reduced in Aloxe3-
overexpressing animals. In striking contrast, WD-fed Aloxe3-overexpressing PPARγ-LKO mice had a signifi-
cantly elevated AUC when compared with WD-fed Aloxe3-overexpressing mice harboring WT hepatic PPARγ.
Figure 6. Hepatic PPARγ is required for Aloxe3 to induce hepatic energetic inefficiency. (A) RNA-seq analysis of the top 5 downregulated molecular 
processes in hepatocytes overexpressing Aloxe3. Highlighted are ATPase-related and mitochondrial coupling processes. Graphed is logFC relative to 
cultures expressing β galactosidase. n = 3 from a single RNA sequencing run performed once. (B and C) Seahorse XF96 analysis of proton leak, basal 
OCR, ATP production, coupling efficiency, and nonmitochondrial oxygen consumption in AML12 cells overexpressing Aloxe3 with or without GW9662 
(PPARγ inhibitor) treatment. n = 8 independent cultures combined from 2 distinct experimental runs. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 
0.0001 by 2-tailed t testing with Bonferroni-Dunn post hoc correction versus the bracketed comparison group as indicated.
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Discussion
The concept of  the fasting and caloric restriction response as a therapeutic to be leveraged in longevi-
ty, healthspan, and metabolism from rodents to early primates to humans (1, 38–43) is gaining traction. 
Already in the clinical realm, caloric restriction improved multiple indices related to aging, cardiovascular 
disease, and diabetes mellitus (2, 44–46). However, strict and prolonged adherence to caloric restriction, 
intermittent fasting, or any intensive dietary restriction directed toward weight loss carries with it sev-
eral practical barriers. Therefore, identifying the therapeutic determinants of  the hepatic glucose fasting 
response opens the promise of  novel, targeted, and sustainable treatments against metabolic and other dis-
eases. Here, we show that Aloxe3 is activated by the adaptive hepatic fasting response and is itself  sufficient 
to enhance insulin sensitivity, increase basal caloric expenditure, and reduce diet-induced weight gain and 
fat accumulation, hepatic steatosis, and dyslipidemia.
Figure 7. Reduced hepatic steatosis correlates with Aloxe3-induced fasting and reduction of de novo lipogenesis. (A) H&E staining in livers from 
low-fat or high–trans fat/cholesterol–fed mice overexpressing empty vector or Aloxe3. (B) Hepatic tissue triglyceride quantification in db/db mice 
overexpressing GFP or Aloxe3 in the presence or absence of GW9662. (C and D) qPCR quantification of expression for oxidative and fasting-response 
genes (C) and de novo lipogenic genes (D) in db/db mice expressing GFP or Aloxe3 with or without GW9662 administration. Number of mice in each 
group is: 10, db/db AAV8GFP; 10, db/db AAV8ALOXE3; 10, AAV8ALOXE3 + GW9662. Scale bar: 100 μm. **P < 0.01, or ****P < 0.0001 by 2-tailed t testing with 
Bonferroni-Dunn post hoc correction versus the bracketed comparison group as indicated.
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Figure 8. Enhanced whole-body energy metabolism in db/db diabetic mice overexpressing Aloxe3. (A) Body weight over time in db/db mice 
expressing empty vector or Aloxe3 in the presence or absence of GW9662. (B) Heat generation over time in db/db mice expressing GFP or Aloxe3. (C 
and D) Indirect calorimetric quantification of light- and dark-cycle heat generation in db/db mice expressing Aloxe3 or GFP treated with or without 
GW9662. (E) Fasting serum insulin determined by ELISA, serum glucose determined by colorimetric assay, and calculated HOMA-IR index based on 
glucose and insulin data. (F–I) Serum TG, cholesterol, LDL-C, and FFA content in db/db mice with or without hepatic Aloxe3 overexpression and with 
or without GW9662 treatment. Number of mice in each group is: 10, db/db AAV8GFP; 10, db/db AAV8ALOXE3; 10, AAV8ALOXE3 + GW9662. *P < 0.05, **P < 
0.01, ***P < 0.001, and < 0.0001 by 2-tailed t test with Bonferroni-Dunn post hoc correction versus bracketed comparison groups.
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Fully defining the metabolic functions of  Aloxe3 has been previously limited by its basal tissue 
expression and distribution and by the dramatic phenotype observed in animals and humans deficient 
for this enzyme. Aloxe3 was first identified as an epidermal-type lipoxygenase that mediates skin dif-
ferentiation via hydroperoxide isomerase activity (27, 47). Humans born with a defect in this gene 
develop ichthyosiform disease, characterized by profound skin barrier dysfunction and transepidermal 
water loss (28, 30). This was confirmed in murine models of  Aloxe3 deficiency, which succumb to mas-
sive dehydration without intervention shortly after birth (32). Subsequent work demonstrated a role 
for Aloxe3 in adipocyte differentiation via PPARγ agonism in cultured adipocytes, as well (29). This 
introduced the possibility that Aloxe3 has important functions that extend beyond epidermal tissues. 
However, a potential function in liver was largely ignored, perhaps in part because nonfasting mRNA 
is relatively low when compared with epidermis and tongue by Northern blot detection (32) and by 
reverse transcription PCR analysis of  murine liver (48). However, we show here that serum and glucose 
withdrawal, trehalose and lactotrehalose (trehalose analog) treatment in vitro, trehalose feeding, and 
acute fasting in vivo each robustly induce Aloxe3 mRNA expression. This raised the prospect that Aloxe3 
mediates part of  the physiological hepatic fasting response. We postulate that the observed increased 
insulin sensitivity in hepatic Aloxe3–overexpressing mice reflects an adaptive response that enhances 
peripheral insulin sensitivity in preparation for a subsequent meal after prolonged fasting. This function 
would be particularly useful to maximize macronutrient absorption for animals in which meals are few 
and far between (e.g., intermittently fasting or hibernating animals). Indeed, this teleological rationale 
has been proposed for other physiological fasting-induced pathways, such as FGF21 signaling (49, 50).
The data herein demonstrate that Aloxe3 ameliorated the diet-induced obesity and db/db diabetic phe-
notypes, at least in part, via a PPARγ-dependent mechanism — most prominently with regard to the insu-
lin-sensitizing effects of  Aloxe3. Aloxe3 overexpression and trehalose treatment in hepatocytes induced the 
PPARγ ligand 12-KETE at cellular concentrations that appear to be physiologically relevant (19). Indeed, 
12-KETE induced sebocyte PPARγ signaling at ~1,500 ng/ml (19), whereas our calculated 12-KETE con-
centrations in Aloxe3-overexpressing hepatocytes (accounting for a hepatocyte volume of  roughly 3 fL, fem-
toliters; ref. 51) indicate concentration of  12-KETE is in the range of  1,000 ng/ml (Figure 2C). In addition, 
PPARγ blockade by GW9662 administration in isolated hepatocytes and in vivo reversed Aloxe3-mediated 
changes in hepatocyte oxygen consumption rate, insulin resistance, and PGC1α upregulation. Finally, liv-
er-specific PPARγ deletion abrogated Aloxe3-enhanced insulin sensitivity. Together, these data introduce 
a potentially novel hepatic Aloxe3–PPARγ axis that improves whole-body insulin sensitivity. These find-
ings are consistent with the previously demonstrated control of  peripheral insulin sensitivity via hepatic 
PPARγ in ob/ob mice (34, 35). However, given that GW9662 did not significantly reverse Aloxe3 effects on 
Figure 9. Insulin sensitization by Aloxe3 requires hepatic PPARγ. (A) Insulin tolerance testing in WT or PPARγ-LKO mice expressing hepatic GFP 
or Aloxe3 after chow or Western diet. (B) Quantification of total area under the glucose time curve.  **P < 0.01 and ***P < 0.001 by 2-tailed t test 
with Bonferroni-Dunn post hoc correction between bracketed comparison groups as indicated. Number of mice in each group is: 4, AAV8GFP Chow; 5, 
AAV8GFP WD; 5, AAV8ALOXE3 WD; and 4, PPARγ-LKO AAV8ALOXE3 WD.
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hepatic fat accumulation and whole-body thermogenesis, our data indicate that Aloxe3 exerts both PPARγ-
dependent and -independent functions to enhance hepatic and extrahepatic metabolic homeostasis.
It should be noted that genetic disruption of  both 12-LOX and 15-LOX in multiple diabetic models 
largely recapitulates the Aloxe3-mediated enhancement of  hepatic insulin sensitivity and reduced hepatic 
steatosis (15–17). Therefore, it is plausible that — in addition to (or perhaps in lieu of) generating the 
PPARγ ligand 12-KETE — eLOX3 either depletes 12-LOX products 12-HpETE and 12-HETE (Figure 2) 
to the host’s benefit, or 12-LOX and 15-LOX deletion shunts arachidonic acid down the eLOX3 enzymatic 
pathway to activate PPARγ. A third distinct possibility is that Aloxe3 mediates its PPARγ-activating effects 
independently of  upstream lipoxygenases. Three key pieces of  data support this possibility. First, hepato-
cytes are not considered overall to be a significant source of  total lipoxygenase activity. This is confirmed 
by our own data suggesting that basal intrinsic hepatocyte lipoxygenase activity is relatively low — on the 
order of  1–10 fmol/mg/min (Figure 2B). Second, eLOX3 exhibits latent intrinsic dioxygenase activity, 
although this catalysis is relatively inefficient when compared with its hydroperoxide isomerase activity 
(31). Third, in adipose tissue, eLOX3 generated PPARγ agonists in the absence of  identifiable upstream 
lipoxygenases (29). However, regardless of  the origin and fate of  the lipid intermediaries going through 
the Aloxe3 pathway, the net benefit of  Aloxe3 expression involves both PPARγ-dependent and -independent 
pathways. The species, origin, and precise bioactivity of  the lipid intermediaries that underlie these thera-
peutic effects now arise as a rich topic for further interrogation.
The current study examines therapeutic effects of  hepatic Aloxe3 induction. From a clinical therapeutic 
perspective, virus-based genetic therapy for many monogenic diseases has already reached clinical care 
(52). However, this therapeutic approach is not yet fully optimized for polygenic diseases, such as obesity, 
insulin resistance, and NAFLD (53). Although our physiological, morphometric, and liver histological 
data did not reveal problematic effects of  Aloxe3 gene overexpression after 12 weeks (Figure 4, Figure 5, 
and Supplemental Figure 4), a genetic overexpression approach at present is likely to be a more distant 
clinical therapy when compared with precision small-molecule therapeutics. In addition, although the full 
extent of  Aloxe3 regulation has yet to be elucidated as a means to leverage Aloxe3-enhancing pathways, we 
demonstrated here that Aloxe3 is potently upregulated by generalized stimuli such as fasting, trehalose feed-
ing, serum withdrawal, and flavone-class GLUT inhibition. In contrast, canonical fasting intermediates 
AMPK, PGC1α, FGF21, and PPARα were dispensable for trehalose-induced Aloxe3 expression. Accord-
ingly, SIRT1 overexpression was insufficient to upregulate Aloxe3 in vivo. It is therefore intriguing that we 
were able to achieve enhanced in vitro Aloxe3 upregulation comparable with viral Aloxe3 overexpression by 
treatment with the trehalase-resistant trehalose analogue lactotrehalose (21–23, 54, 55). Our characteriza-
tion of  this glucose-galactose trehalose analogue, and the finding that lactotrehalose exhibits enhanced 
fasting-mimetic potency, is a critical advance for at least 2 reasons. First, abundant trehalase expression in 
human gut, liver, brain, kidney, and reproductive tissues raises the possibility that trehalose-based therapies 
may be limited by trehalase-mediated trehalose degradation. By corollary, trehalase-resistant compounds 
such as lactotrehalose are postulated to confer enhanced efficacy. Secondly, it is well understood that 
GLUT8 and GLUT2 (the 2 most highly expressed hepatic glucose transporters; ref. 7) are competitively 
inhibited by galactose (56–58). In light of  the fact that galactose is one of  the saccharide moieties that com-
prises lactotrehalose, the data suggest that altering the saccharide moieties in trehalose modulates potency 
(and perhaps also selectivity) based on each GLUT’s substrate predilection.
Taken together, although greater detail regarding intermediary regulation of  Aloxe3 is warranted, aug-
menting Aloxe3 expression and other components of  the hepatic fasting response is now feasible through 
fasting itself, glucose withdrawal, or trehalose/analogue-class GLUT inhibition. The palatability, and 
heavy first-pass enterohepatic kinetics (which minimizes peripheral tissue GLUT side effects) indeed make 
trehalose and its analogues especially attractive candidate nutraceuticals to elicit this response. Future 
directions should interrogate the fasting response–inducing potential, kinetics, and efficacy of  trehalose 
and its analogs in mitigating metabolic disease (21, 25, 59). In addition, it will be critical to understand 
the extent to which Aloxe3 regulation in other tissues is necessary or sufficient to augment tissue-specific 
adaptive fasting responses. Finally, understanding the full cadre of  epoxyalcohols and other lipid products 
of  eLOX3 enzymatic activity, and their specific roles in the mitigating metabolic disease, are of  special 
pharmaceutical and clinical interest (15, 60–63).
In summary, we identified the lipoxygenase Aloxe3 as a potentially novel effector of  the hepatic fast-
ing response that is sufficient to augment basal caloric expenditure, and ameliorate insulin resistance, 
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weight gain, and hepatosteatosis.  (the meaning I hope to convey is that Aloxe3 does all of  the above). 
The rapidly rising prevalence of  each of  these major public health problems throughout the Western 
and developing worlds mandates novel therapeutic pathway generation and leveraging thereof. We 
assert that further interrogation into how hepatic glucose transport mediates the networked adaptive 
hepatic fasting response will advance the field toward new and effective human therapy against meta-
bolic disease.
Methods
Mouse models and treatment. All mice were caged in specific pathogen-free barrier housing with 12-hour 
light-dark cycles and free access to water and rodent chow. For transgenic studies, WT C57B/6J mice and 
Leprdb/db mice were obtained directly from the Jackson Laboratory. Upon arrival, mice were randomized to 
experimental assignments and equilibrated for a minimum of  7 days in the specific pathogen-free vivarium 
with automated 12-hour light-dark cycles and free access to water and rodent chow. Prior to initiating 
metabolic measurements. ATG16L1HM mice were a provided by Herbert “Skip” W. Virgin’s laboratory 
(Washington University School of  Medicine) (64). PPARγ-LKO mice were obtained directly from the 
Jackson Laboratory to the laboratory of  David Rudnick (Washington University School of  Medicine) 
and, after propagation, were provided for experimentation.
Adeno-associated viruses overexpressing either GFP or Aloxe3 under control of  the thyroid bind-
ing globulin (TBG) promoter were obtained as ready-to-use viral stocks from Vector Biolabs. Viral 
particles (1 × 1011 per animal) were injected via tail vein in 6-week-old mice 10 days prior to dietary 
initiation or 38 days prior to sacrifice in the genetic obesity model (e.g., 10 days rest period + 28 day 
dietary stimulus) Aloxe3 expression was quantified in pilot experiments by qPCR analysis of  hepatic 
tissue, skeletal muscle tissue, and brown and epididymal WAT 10 days after injection and confirmed 
selective hepatic Aloxe3 overexpression (not shown).
Antisense oligonucleotides (ASOs) were obtained from IONIS Pharmaceuticals as ready-to-inject 
oligomers, and they were used precisely as described previously (65). GW9662 was obtained from Cayman 
Chemicals (catalog 70785). WD is from Harlan Teklad (catalog TD88137); HTF-C diet is from Research 
Diets (catalog 09100301).
Lactotrehalose synthesis and purification. Synthesis and purification of  lactotrehalose was carried out pre-
cisely as described (66). We confirmed 98%–99% purity by 1H-NMR (not shown).
Lipoxygenase activity assay. LOX activity was quantified using a lipoxygenase activity assay kit (Biovi-
sion, catalog 978-100) per manufacturer instructions.
Serum analyses. Fasting blood glucose was measured via glucometer using tail vein blood. For all other 
serum analyses, submandibular blood collection was performed immediately prior to sacrifice, and serum 
was separated. Insulin ELISA (MilliporeSigma, catalog EZRMI-13K), TG (Thermo Fisher Scientific, cata-
log TR22421), cholesterol (Thermo Fisher Scientific, catalog TR13421), and free FA (FFA) (Wako Diag-
nostics, catalog 999-34691, 995-34791, 991-34891, and 993-35191) quantification was performed using 
commercially available reagents according to manufacturer’s directions. Albumin levels were quantified 
using an AMS LIASYS Chemistry Analyzer.
Hepatic lipids. Lipids were extracted from ~100 mg hepatic tissue homogenized in 2:1 chloroform/
methanol. Extract (0.25%–0.5% of  each) was evaporated overnight prior to biochemical quantification of  
TGs, LDL-C, cholesterol, and FFA using reagents described above, according to manufacturer’s directions.
Oil Red O staining. Methanol-fixed frozen sections from WT and transgenic mice were stained accord-
ing to described protocols (7, 9, 12).
Body composition analysis and indirect calorimetry. Body composition analysis was carried out in unanes-
thetized mice as described (7, 8, 67) using an EchoMRI 3-1 device (Echo Medical Systems) via the Wash-
ington University Diabetic Mouse Models Phenotyping Core Facility.
The first 4 hours in the cage were unmeasured in order to allow for acclimation time. Thereafter, the 
oxygen and CO2 consumption and production were quantified for a minimum of  1 light cycle (0601–
1800 hours) and for 1 dark cycle (1801–0600 hours). Volume O2 (VO2 ), VCO2, heat, movement, and 
respiratory exchange ratio (RER) were automatically calculated using TSE Phenomaster software.
In vitro metabolism (Seahorse XF96) assays. Seahorse assays were performed using a Seahorse XF96 ana-
lyzer Mito Stress Test Kit (Agilent Technologies) according to manufacturer specifications. Hepatocyte 
cultures were seeded at 20,000 cells per well prior to assay.
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Immunoblotting. Immunoblotting was performed as described (67).  Anti-GAPDH (catalog 5174) was 
obtained from Cell Signaling Technologies. LC3B antiserum was obtained from Novus Biologicals (catalog 
NB-100-2200).
Indirect calorimetry. Oxygen consumption, CO2 production, RER, and heat production were measured 
using the Phenomaster system (TSE) via the Washington University Diabetic Mouse Models Phenotyping 
Core Facility as described (8, 67). Metabolic parameters were documented every 13 minutes.
Cell cultures and treatment. Primary murine hepatocytes obtained from WT mice were isolated as 
described (7, 9–11) and cultured and maintained in regular DMEM growth media (MilliporeSigma, cat-
alog D5796) containing 10% FBS. For in vitro starvation experiments, starved media containing 1 g/l 
glucose and 0.5% FBS was used. Cultures were lysed in Trizol and subjected to downstream analysis. In 
vitro genetic knockdown was achieved via siRNA transfection using Lipofectamine 3000 from Invitrogen 
(catalog L3000015). Trehalose was obtained from MilliporeSigma and was >97% purity by HPLC. Tre-
halose water (3%, w/v) fed ad libitum was used in all in vivo experiments. Huh7 and HepG2 cell lines 
were obtained directly from the American Type Culture Collection (ATCC). Human primary hepatocyte 
cDNAs were obtained directly from Sciencell (catalog 5204).
qPCR. qPCR was performed as previously reported (7, 12) with some modifications. Snap-frozen livers 
or cultured hepatocytes were homogenized in Trizol reagent (Invitrogen, catalog 15596026). RNA isolated 
according to the manufacturer’s protocol was reverse-transcribed using the Qiagen Quantitect reverse tran-
scriptase kit (Qiagen, catalog 205310). cDNA was subjected to qPCR using the SYBR Green master mix 
reagent (Applied Biosystems, catalog 4309155). Expression data are depicted as a mean ratio of  target gene 
expression relative to 36B4 (housekeeping gene) expression in each sample, ± SEM. Primer sequences for 
qPCR are shown in Supplemental Table 1.
RNA-seq. RNA-seq was performed by the Washington University Genome Technology Access Center 
(GTAC). Primary data, processed data, and metadata for these experiments were deposited in the Gene 
Expression Omnibus (www.ncbi.nlm.nih.gov/geo), with accession number GSE116516.
Library preparation was performed with 10 μg of  total RNA with a Bioanalyzer RIN score greater than 
8.0. Ribosomal RNA was removed by poly-A selection using Oligo-dT beads (mRNA Direct kit, Invitro-
gen). mRNA was then fragmented in buffer containing 40 mM tris acetate pH 8.2, 100 mM potassium ace-
tate, and 30 mM magnesium acetate and heated to 94°C for 150 seconds. mRNA was reverse transcribed 
to yield cDNA using SuperScript III RT enzyme (Invitrogen, per manufacturer’s instructions) and random 
hexamers. A second strand reaction was performed to yield double-stranded cDNA (ds-cDNA). cDNA was 
blunt ended, had an A base added to the 3′ ends, and then had Illumina sequencing adapters ligated to the 
ends. Ligated fragments were then amplified for 12 cycles using primers incorporating unique index tags. 
Fragments were sequenced on an Illumina HiSeq-3000 using single reads extending 50 bases.
RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b. 
Gene counts were derived from the number of  uniquely aligned unambiguous reads by Subread:featureCount 
version 1.4.5. Transcript counts were produced by Sailfish version 0.6.3. Sequencing performance was 
assessed for total number of  aligned reads, total number of  uniquely aligned reads, genes and transcripts 
detected, ribosomal fraction known junction saturation, and read distribution over known gene models 
with RSeQC version 2.3.
To enhance the biological interpretation of  the large set of  transcripts, grouping of  genes/transcripts 
based on functional similarity was achieved using the R/Bioconductor packages GAGE and Pathview. 
GAGE and Pathview were also used to generate pathway maps on known signaling and metabolism path-
ways curated by Kyoto Encyclopedia of  Genes and Genomes (KEGG).
Liquid chromatography-tandem mass spectral analysis of  eicosanoids. Eicosanoids (5-HETE, 12-HETE, and 
12-KETE) were extracted with 300 μl of  1:1 methanol/water, containing 2 ng deuterated 12-HETE-d8 
(Cayman Chemical) as the internal standard. This extract (33% of  total) was injected; therefore, 0.67 ng 
represents the total internal standard analyzed. The quantity of  eicosanoids calculated based on the peak 
are the ratio between the analyte and internal standard. Eicosanoid and internal standard analyses were 
performed using a Shimadzu 20AD HPLC system, and a LeapPAL autosampler coupled to a tandem 
mass spectrometer (API 4000, API-Sciex). These were operated in negative ion MRM mode. The sample 
was injected on to a Thermo-Keystone betasil C-18 HPLC column (2 × 100 mm, 3 μm) with mobile 
phases (A, 5 mM ammonium fluoride in water; B, 100 % acetonitrile). The data processing was conducted 
with Analyst 1.6.3 (API-Sciex).
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ITT. ITT was performed precisely as reported previously (8). Briefly, mice were fasted 4 hours prior to 
i.p. administration of  0.75 U/kg insulin. Glucose was monitored by glucometer (One Touch Ultra, Lifes-
can) over the course of  2 hours following injection.
Statistics. Data were analyzed using GraphPad Prism version 6.0 (RRID:SCR_015807). A P value 
less than 0.05 was defined as statistically significant. Data shown are as mean ± SEM. Unpaired 2-tailed 
homoscedastic t tests with Bonferroni post hoc correction for multiple comparisons were used for all analy-
ses unless otherwise noted in the figure legends. Two-way ANOVA was also used for analyses with 2 inde-
pendent variables.
Study approval. All animal procedures were reviewed and approved by the Washington University 
School of  Medicine Animal Studies Committee.
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